Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Werewolf Therapeutics (HOWL) Cash from Financing Activities (2021 - 2025)

Werewolf Therapeutics (HOWL) has disclosed Cash from Financing Activities for 5 consecutive years, with $3.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Financing Activities rose 54666.67% to $3.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $6.2 million, a 68.33% decrease, with the full-year FY2024 number at $13.1 million, down 77.61% from a year prior.
  • Cash from Financing Activities was $3.3 million for Q3 2025 at Werewolf Therapeutics, up from $388000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $110.2 million in Q2 2021 to a low of -$9.7 million in Q2 2024.
  • A 5-year average of $11.1 million and a median of $974000.0 in 2022 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: plummeted 1504.62% in 2024, then skyrocketed 54666.67% in 2025.
  • Werewolf Therapeutics' Cash from Financing Activities stood at $38000.0 in 2021, then skyrocketed by 3205.26% to $1.3 million in 2022, then skyrocketed by 622.37% to $9.1 million in 2023, then plummeted by 71.93% to $2.5 million in 2024, then grew by 28.54% to $3.3 million in 2025.
  • Per Business Quant, the three most recent readings for HOWL's Cash from Financing Activities are $3.3 million (Q3 2025), $388000.0 (Q2 2025), and $2.5 million (Q4 2024).